ScholarMate
English简体中文繁體中文
客服熱線:400-1616-289
登入註冊
期刊論文

Association of chemotherapy with survival in stage II colon cancer patients who received radical surgery: a retrospective cohort study

Lv, Zhihao*; Liang, Yuqi; Liu, Huaxi; Mo, Delong广州中医药大学; 南方医科大学
BMC CANCER2021-3-23DOI: 10.1186/s12885-021-08057-3
10被引12閱讀
引用收藏
分享

摘要

BackgroundIt remains controversial whether patients with Stage II colon cancer would benefit from chemotherapy after radical surgery. This study aims to assess the real effectiveness of chemotherapy in patients with stage II colon cancer undergoing radical surgery and to construct survival prediction models to predict the survival benefits of chemotherapy.MethodsData for stage II colon cancer patients with radical surgery were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching (1:1) was performed according to receive or not receive chemotherapy. Competitive risk regression models were used to assess colon cancer cause-specific death (CSD) and non-colon cancer cause-specific death (NCSD). Survival prediction nomograms were constructed to predict overall survival (OS) and colon cancer cause-specific survival (CSS). The predictive abilities of the constructed models were evaluated by the concordance indexes (C-indexes) and calibration curves.ResultsA total of 25,110 patients were identified, 21.7% received chemotherapy, and 78.3% were without chemotherapy. A total of 10,916 patients were extracted after propensity score matching. The estimated 3-year overall survival rates of chemotherapy were 0.7% higher than non- chemotherapy. The estimated 5-year and 10-year overall survival rates of non-chemotherapy were 1.3 and 2.1% higher than chemotherapy, respectively. Survival prediction models showed good discrimination (the C-indexes between 0.582 and 0.757) and excellent calibration.ConclusionsChemotherapy improves the short-term (43months) survival benefit of stage II colon cancer patients who received radical surgery. Survival prediction models can be used to predict OS and CSS of patients receiving chemotherapy as well as OS and CSS of patients not receiving chemotherapy and to make individualized treatment recommendations for stage II colon cancer patients who received radical surgery.

學科與關鍵詞

關鍵詞
Colon cancerSEERChemotherapyNomogramCompeting-risk model
相關
載入中…
  • Real-world survival of colon cancer after radical surgery: A single-institutional retrospective analysis
    Pang, Xiangyi; Xu, Benjie; Lian, Jie; Wang, Ren; Wang, Xin; Shao, Jiayue; Tang, Shuli; Lu, Haibo*Frontiers in Oncology, 2022, 12: 914076.被引 4
  • Adjuvant chemotherapy benefits on patients with elevated carcinoembryonic antigen in stage IIA colon cancer: a SEER-based analysis
    Zhou, Huabin; Wang, Songsheng; Cai, Zhai; Qiu, Enming; Chen, Qianyun; Rao, Xi; Han, Shuai; Li, Zhou*INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2022, 37(12): 2481-2489.
  • Prognostic value of final pathological stage in colon adenocarcinoma after neoadjuvant chemotherapy: A propensity score-matched study
    Xiang, Meijuan; Liang, Zongyu; Gao, Yuan; Feng, Xingyu*; Yao, Xueqing*Frontiers in Surgery, 2022, 9: 1022025.被引 1
查看全部 →

發表資訊

論文狀態
公開發表
期刊
BMC CANCER
發表日期
2021-03-23
卷期
第 21 卷, 第 1 期
頁碼
306
DOI
10.1186/s12885-021-08057-3
語言
ENGLISH
期刊收錄
NSL
期刊等級
2区
成果收錄
SCIE

作者

  • L

    Lv, Zhihao (通訊) (第一作者)

    guangzhou univ chinese med

  • L

    Liang, Yuqi

    guangzhou univ chinese med

查看全部 4 位作者收起作者
  • L

    Liu, Huaxi

    southern med univ

  • M

    Mo, Delong

    guangzhou univ chinese med

登入解鎖更多功能

  • 收藏這篇,隨時在「我的 · 收藏」找回
  • 認領你的成果,生成推廣素材
  • 關注作者獲取最新成果
  • 加入項目組、協同寫作
註冊 / 登入

產品服務

  • 科研之友
  • 創新城
  • 科創雲

服務支援

  • 幫助中心
  • 隱私政策
  • 服務條款

聯絡方式

線上客服:【】
客服熱線:400-1616-289
電子郵件:support@scholarmate.com

關注或下載科研之友

微信 QR Code
微信公眾號
客戶端下載 QR Code
下載客戶端
科研成果科研人員科研機構科研動態愛瑞思軟件

©2026 深圳市科研之友网络服务有限公司

公安備案圖示粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417